6,889 research outputs found
Genetic clonal mapping of in situ and invasive ductal carcinoma indicates the field cancerization phenomenon in the breast
Summary Nearly 80% of well-differentiated in situ duct carcinomas (g1 DCIS) have been shown to be multicentric (multilobar) lesions, while most in situ poorly differentiated duct carcinomas (g3 DCIS) were unifocal (unilobar) lesions. Here we present a clonality study of 15 cases of DCIS, all showing multiple foci. Twelve of these cases were associated with an invasive duct carcinoma. Fifteen cases of female breast cancer patients all showing multiple DCIS foci (5 g1 DCIS, 5 g2 DCIS, 5 g3 DCIS) were randomly selected and histologically studied using large histological sections. Care was taken to laser-microdissect DCIS foci that were most distantly located from one another in the same large section, and pertinent cells were genetically studied. Invasive duct carcinoma and ipsilateral lymph node metastases and/or contralateral lesions, whenever present, were additionally microdissected. DNA of neoplastic cells was purified, and the mtDNA D-loop region was sequenced. Genetic distance of different foci from the same case was visualized by phylogenetic analyses using the neighbor-joining method. Patients ranged in age from 36 to 87 years (mean 65.1). All 9 cases of widely spread DCIS were not clonal. Four of 6 cases that showed multiple adjacent foci were clonally related on mtDNA analysis. In the present series, 11/15 DCIS appeared as multiple synchronous primary breast tumors, genetically not related to one another. The present data enhance the view that breast can also show the field cancerization phenomenon, paralleling what has already been proposed in other organs
Calcitonin free oat-cell carcinoma of the thyroid gland
Two cases of primary oat-cell carcinoma of thyroid, in a 63-year-old woman and a 73-year-old man, are described. Case 1 was a compound tumour with the oat-cell component merging with a papillary component. Both tumours, in addition to histological features consistent with oat-cell carcinoma, showed immunohistochemical positivity with anti-chromagranin A and anti-synaptophysin antisera. Negative results were obtained when anti-calcitonin and anti-thyroglobulin antisera were employed. Using in situ hybridization, chromogranin A and B messenger RNAs were localized with biotinylated oligonucleotide probes. In contrast, with in situ hybridization, no localization for calcitonin messenger RNA was seen using radioactive and biotinylated probes. It is concluded that these calcitonin-free, small-cell carcinomas should be considered separately from medullary thyroid carcinomas and be regarded as a distinct entity, probably the thyroid equivalent of oat-cell carcinomas of the lung.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/47516/1/428_2005_Article_BF01600144.pd
Epidemic and Cascading Survivability of Complex Networks
Our society nowadays is governed by complex networks, examples being the
power grids, telecommunication networks, biological networks, and social
networks. It has become of paramount importance to understand and characterize
the dynamic events (e.g. failures) that might happen in these complex networks.
For this reason, in this paper, we propose two measures to evaluate the
vulnerability of complex networks in two different dynamic multiple failure
scenarios: epidemic-like and cascading failures. Firstly, we present
\emph{epidemic survivability} (), a new network measure that describes the
vulnerability of each node of a network under a specific epidemic intensity.
Secondly, we propose \emph{cascading survivability} (), which characterizes
how potentially injurious a node is according to a cascading failure scenario.
Then, we show that by using the distribution of values obtained from and
it is possible to describe the vulnerability of a given network. We
consider a set of 17 different complex networks to illustrate the suitability
of our proposals. Lastly, results reveal that distinct types of complex
networks might react differently under the same multiple failure scenario
A knowledge discovery framework to predict the N2O emissions in the wastewater sector
Horizon 2020 research and innovation program SMART-Plant (grant agreement No 690323
Operational experience, improvements, and performance of the CDF Run II silicon vertex detector
The Collider Detector at Fermilab (CDF) pursues a broad physics program at
Fermilab's Tevatron collider. Between Run II commissioning in early 2001 and
the end of operations in September 2011, the Tevatron delivered 12 fb-1 of
integrated luminosity of p-pbar collisions at sqrt(s)=1.96 TeV. Many physics
analyses undertaken by CDF require heavy flavor tagging with large charged
particle tracking acceptance. To realize these goals, in 2001 CDF installed
eight layers of silicon microstrip detectors around its interaction region.
These detectors were designed for 2--5 years of operation, radiation doses up
to 2 Mrad (0.02 Gy), and were expected to be replaced in 2004. The sensors were
not replaced, and the Tevatron run was extended for several years beyond its
design, exposing the sensors and electronics to much higher radiation doses
than anticipated. In this paper we describe the operational challenges
encountered over the past 10 years of running the CDF silicon detectors, the
preventive measures undertaken, and the improvements made along the way to
ensure their optimal performance for collecting high quality physics data. In
addition, we describe the quantities and methods used to monitor radiation
damage in the sensors for optimal performance and summarize the detector
performance quantities important to CDF's physics program, including vertex
resolution, heavy flavor tagging, and silicon vertex trigger performance.Comment: Preprint accepted for publication in Nuclear Instruments and Methods
A (07/31/2013
Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers
Abstract Background Central nervous system (CNS) spreading from epithelial ovarian carcinoma (EOC) is an uncommon but increasing phenomenon. We previously reported in a small series of 11 patients a correlation between Androgen Receptor (AR) loss and localization to CNS. Aims of this study were: to confirm a predictive role of AR loss in an independent validation cohort; to evaluate if AR status impacts on EOC survival. Results We collected an additional 29 cases and 19 controls as validation cohort. In this independent cohort at univariate analysis, cases exhibited lower expression of AR, considered both as continuous (p < 0.001) and as discrete variable (10% cut-off: p < 0.003; Immunoreactive score: p < 0.001). AR negative EOC showed an odds ratio (OR) = 8.33 for CNS dissemination compared with AR positive EOC. Kaplan-Meier curves of the combined dataset, combining data of new validation cohort with the previously published cohort, showed that AR < 10% significantly correlates with worse outcomes (p = 0.005 for Progression Free Survival (PFS) and p = 0.002 for brain PFS (bPFS) respectively). Comparison of AR expression between primary tissue and paired brain metastases in the combined dataset did not show any statistically significant difference. Conclusions We confirmed AR loss as predictive role for CNS involvement from EOC in an independent cohort of cases and controls. Early assessment of AR status could improve clinical management and patients’ prognosis
- …